Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Press release

<< Previous

Bullboard Posts

Next >>

Comment by Goaweighon Feb 23, 2021 6:41pm

252 Views

Post# 32642991

RE:RE:RE:Press release

If you've been here for 22 years you have every right to be sarcastic, I would have been 20 years ago. Now maybe it's the CAT T side of the equation that's relatively new hence the mice studies or maybe any new combination of drugs, even two components that have both passed PH 3 on their own still require early stage animal studies when combined. Just a thought.
It seems to me that every time anyone adds Pelareorep to their own drug it makes that drug just that more effective. How many differant trials/partners are we working on/with now and when is one of these major's going to figure this out.

Maybe we need to do some marketing

" Pelareorep, You can put that...with anything" !